ARID1A and prostate neoplasm: As ARID1A mutations are believed to result in reduced gene expression [9], we performed immunohistochemical staining with a specific antibody against ARID1A, which revealed complete loss of expression in all tumor cells, further confirming the loss-of-function mutation of ARID1A in this prostatic tumor.